RESUMEN
PURPOSE: The intent of this work was to assess the impact of lyophilization on the encapsulation of salmon calcitonin (sCT) into liposomes. METHODS: Four different liposomal formulations were investigated, i.e. DPPC:Chol:DSPE-PEG(2000) (75:20:5 and 65:30:5) and DPPC:Chol (80:20 and 66.7:33.3). Lipid films were prepared and hydrated with loading buffer containing sCT and different concentrations of the cryoprotectant, trehalose dihydrate. The liposomes were lyophilized, reconstituted and extruded to obtain small unilamellar vesicles. Non-encapsulated sCT was separated by gel filtration. Non-lyophilized formulations and liposomes lyophilized without the cryoprotectant were used as controls. Liposomes were analyzed for particle size, polydispersity index, zeta-potential and encapsulation efficiency. ³¹P-NMR (phosphorous nuclear magnetic resonance spectroscopy) was performed on selected formulations. RESULTS: Post-lyophilization, no significant change in particle sizes and zeta-potentials were noted, regardless of the presence or absence of the cryoprotectant. Encapsulation efficiencies, however, increased following lyophilization, in both PEGylated (lyophilization control batch) and non-PEGylated liposomes (cryoprotectant batches only). ³¹P-NMR revealed the presence of two distinct vesicle populations--liposomes and micelles--in PEGylated formulation. The presence of micelles might be responsible for the observed encapsulation enhancement of sCT in the PEGylated formulation. CONCLUSIONS: Lyophilization resulted in an increase in encapsulation efficiency of sCT in PEGylated liposomes, even in the absence of a cryoprotectant, due to presence of micellar vesicles.
Asunto(s)
Conservadores de la Densidad Ósea/química , Calcitonina/química , Portadores de Fármacos/química , Proteínas de Peces/química , Salmón , Animales , Conservadores de la Densidad Ósea/administración & dosificación , Calcitonina/administración & dosificación , Crioprotectores/química , Portadores de Fármacos/administración & dosificación , Composición de Medicamentos , Estabilidad de Medicamentos , Proteínas de Peces/administración & dosificación , Liofilización , Liposomas , Tamaño de la Partícula , Estabilidad Proteica , Trehalosa/químicaRESUMEN
BACKGROUND: Salmon calcitonin (sCT) is approved for the short-term treatment of Paget's disease and hypercalcemia. As pulmonary delivery might improve the drug's efficacy, a variety of liposomal sCT formulations for inhalation were prepared and characterized with the intention of developing a controlled release formulation. METHODS: The influence of pH of the loading buffer, charge of the vesicular surface, and membrane rigidity on particle size, ζ-potential, and sCT encapsulation efficiency of formulations was studied. The most promising systems were investigated for their ability to withstand nebulization stresses using an Aeroneb(®) vibrating mesh device. In vitro studies were carried out to determine sCT release from the vesicles and the bioactivity of the peptide post nebulization. Lastly, pharmacokinetics of sCT liposomes following intratracheal aerosolization in an experimental rat model were investigated and compared with intravenous injection. RESULTS: Liposomes prepared with acidic loading buffer and comprising rigid lipid membranes showed an optimal compromise between small particle size, high encapsulation efficiency, and sCT stability. Polyethylene glycol (PEG) liposomes showed the highest encapsulation efficiency overall, regardless of the ζ-potential of the vesicles. Positive surface charge, however, yielded higher entrapment in non-PEGylated liposomes. All liposomes tested were stable during nebulization. The bioactivity of sCT after formulation into liposomes was 52-55%. Intratracheal nebulization in rats revealed that the bioavailability and other pharmacokinetic parameters were not enhanced by liposomes, when compared with sCT solution. Following intravenous administration, however, liposomes showed significantly higher bioavailability and AUCinf (area under the curve to the infinity time point) than controls. CONCLUSIONS: The developed liposomal formulations were not optimal carriers for pulmonary delivery of sCT. Due to the low amounts of peptide released from the vesicles, enzymatic digestion by peptidases in the airspace reduced the bioavailability significantly. Liposomal encapsulation of sCT, nevertheless, resulted in improved pharmacokinetics following injection.
Asunto(s)
Conservadores de la Densidad Ósea/administración & dosificación , Conservadores de la Densidad Ósea/farmacocinética , Calcitonina/administración & dosificación , Calcitonina/farmacocinética , Portadores de Fármacos , Pulmón/metabolismo , Polietilenglicoles/química , Administración por Inhalación , Animales , Área Bajo la Curva , Disponibilidad Biológica , Conservadores de la Densidad Ósea/química , Neoplasias de la Mama/patología , Tampones (Química) , Calcitonina/química , Línea Celular Tumoral , Química Farmacéutica , Preparaciones de Acción Retardada , Femenino , Concentración de Iones de Hidrógeno , Inyecciones Intravenosas , Liposomas , Masculino , Nebulizadores y Vaporizadores , Tamaño de la Partícula , Ratas , Ratas Wistar , Estrés Mecánico , Propiedades de SuperficieRESUMEN
INTRODUCTION: A number of delivery issues exist for biotech molecules including peptides, proteins and gene-based medicines that now make up over 60% of the drug pipeline. The problems comprise pharmaceutical ad biopharmaceutical issues. One of the common approaches to overcome these issues is the use of a carrier and liposomes as carriers have been investigated extensively over the last decade. AREAS COVERED: The review has been discussed in terms of formulation and preclinical development studies and in vivo studies encompassing different delivery routes including parenteral, oral, buccal, pulmonary, intranasal, ocular and transdermal involving liposomes as carriers. Important research findings have been tabulated under each side heading and an expert opinion has been summarised for each delivery route. EXPERT OPINION: The conclusion and expert opinion - conclusion sections discuss in detail troubleshooting aspects related to the use of liposomes as carriers for delivery of biopharmaceutical moieties and scrutinises the aspects behind the absence of a protein/peptide-containing liposome in market.